Casgevy

Indicated For

sickle cell disease, transfusion-dependent beta thalassemia

About This Medication

# Vertex Connects Patient Guide: How to Get Casgevy at Low or No Cost Casgevy (exagamglogene autotemcel) is a groundbreaking one-time gene therapy approved by the FDA for treating sickle cell disease and transfusion-dependent beta thalassemia. Vertex Connects, offered by Vertex Pharmaceuticals Incorporated, provides comprehensive patient support to help access this therapy, including financial assistance options for commercially insured, Medicare, Medicaid, underinsured, and uninsured patients[1][2]. ## About Casgevy **Casgevy** is a personalized gene therapy that modifies a patient's own stem cells to produce functional red blood cells, addressing the root cause of sickle cell disease (SCD) and beta thalassemia. Unlike daily medications, it's administered once at an Authorized Treatment Center (ATC), where your cells are collected, edited, and reinfused after chemotherapy conditioning[3]. Approved in December 2023 for SCD (ages 12+) and January 2024 for beta thalassemia (ages 12+), Casgevy offers potential for long-term transfusion independence and reduced pain crises. Over 65 ATCs are available in the US, with more expanding globally. The list price is around $2.2 million, but Vertex Connects helps navigate costs through insurance support, copay assistance, and free drug options where eligible[1][3]. This therapy isn't for everyone—eligibility depends on your diagnosis, age, and ability to undergo the intensive process involving hospitalization. Consult your doctor to see if Casgevy fits your treatment plan. ## Who Qualifies for Vertex Connects? Vertex Connects supports patients once Casgevy is prescribed, regardless of insurance status. Key qualifiers include: - A confirmed prescription for Casgevy from your healthcare provider. - Enrollment in the program (not mandatory for therapy but required for assistance offerings). - Needs-based evaluation for financial support[1]. The program welcomes **commercially insured**, **Medicare/Medicaid**, **underinsured**, and **uninsured** patients. No coverage is strictly required, making it accessible for those facing high out-of-pocket costs[1][2]. ## Income Eligibility Breakdown Specific income thresholds (e.g., Federal Poverty Level percentages) are not publicly detailed; eligibility is determined individually during enrollment based on household income, insurance, and financial need. Vertex assesses cases holistically[1]. Here's a general overview in table form (contact program for personalized assessment): | Household Size | Estimated Eligibility Notes | Financial Aid Potential | |----------------|-----------------------------|-------------------------| | Individual | Needs-based review | Copay cards, free drug if uninsured[2] | | Couple | Household income evaluated | Medicare support[1] | | Family of 3 | Full financial disclosure | Bridge programs | | Family of 4+ | Case-by-case | Up to 100% assistance | **Notes:** No fixed FPL limit listed. Uninsured patients may qualify for free medication. Always verify with the program as policies evolve[1]. ## Insurance Requirements Vertex Connects is flexible: - **Commercial Insurance:** Copay savings cards available to reduce out-of-pocket costs[2]. - **Medicare/Medicaid:** Dedicated support for coverage navigation and supplemental aid[1]. - **Underinsured/Uninsured:** Potential for Vertex to cover the full cost post-payer denial[1][3]. Coverage isn't required to start, but Vertex works with payers for prior authorizations and single-case agreements. Over 90 patients have begun treatment with improving reimbursement[3]. ## Step-by-Step Application Process 1. **Get Prescribed:** Discuss Casgevy with your hematologist. If eligible, they'll refer you to an ATC (find via Vertex resources)[3]. 2. **Enroll in Vertex Connects:** Call **(833) 837-8395** (Mon-Fri, 8 AM-8 PM ET). Provide your prescription details[1]. 3. **Complete Enrollment Form:** Your doctor or ATC supplies the form. Submit patient info, insurance details, income proof (e.g., tax returns, pay stubs), and prescription[1]. 4. **Eligibility Review:** Vertex assesses for assistance type (copay help, free drug, travel support). This is needs-based[1]. 5. **Prior Authorization:** Vertex aids your provider in securing insurance approval. 6. **Start Treatment:** Once approved, proceed to ATC for cell collection and therapy. Application is by **phone** only—no online portal listed. Enrollment enhances access to all support[1]. ## Timeline and Delivery Processing timelines vary by insurance and case complexity—expect weeks for enrollment and eligibility, plus months for full therapy (cell collection to infusion). Payer coverage is progressing, with formal agreements in place[3]. Delivery occurs at one of 65+ US ATCs. Vertex coordinates logistics, including potential travel aid. No reauthorization needed for this one-time therapy[1][3]. ## Alternatives if Denied If ineligible: - Explore other PAPs or state assistance. - **Biosimilars:** None available for Casgevy (unique gene therapy)[provided]. - Standard treatments: Hydroxyurea, transfusions, or other SCD/thalassemia therapies. - Appeal denial or reapply with updated info. Contact Vertex for guidance[1]. ## Disclaimer This guide is for informational purposes only and based on available data as of 2026. Program details can change—always call (833) 837-8395 for current eligibility. Not medical advice; consult your healthcare provider. Vertex Pharmaceuticals does not guarantee coverage. Income assessments are private and case-specific[1].

Program information last verified: March 30, 2026